Dendritic cell vaccination trial for hormone refractory prostate cancer with autologous tumour as the antige

Phase 1

Completed

• Conditions: Hormone refractory prostate cancer; Cancer - Prostate

• Registration Number: ACTRN12605000424606
• Lead Sponsor: Queensland Institute of Medical Research (QIMR)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

Histologically proven prostatic Cancer, Maintenance hormone monotherapy, Serum PSA titres rising on 2 consecutive analyses, Minimum 5g of tumour-containing tissue.

Exclusion Criteria

ECOG status >1, Significantly abnormal Haematological parameters, History of autoimmune disease or previous long-term use of immunosuppressive therapy, Positive serology for HIV, Hep C or B, Significant non-malignant disease, Psychiatric, addictive or any conditions which compromise ability to participate in trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety assessed at each vaccination[Every two weeks for 10 weeks and then every 6 weeks for up to 1 year]

Secondary Outcome Measures

Name	Time	Method
PSA levels tested at each vaccination[Every two weeks for 10 weeks and then every 6 weeks for up to 1 year.];Tumour stasis/regression assessed by radiography performed either.[At final assessment or as clinically indicated based on PSA levels.]